<DOC>
	<DOCNO>NCT01425801</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics single dos inhale LAS100977 QD patient persistent asthma .</brief_summary>
	<brief_title>Single Dose Study Assess Efficacy , Safety Tolerability LAS100977 Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Adult male female patient age 1870 year ( include ) . 2 . Clinical diagnosis persistent asthma ( accord GINA guideline 2009 update ) least 6 month prior screen . 3 . Screening FEV1 value 60 % &lt; FEV1 ≤ 85 % predict normal value . 4 . FEV1 reversibility ≥ 12 % absolute increase least 200 ml baseline value inhalation 400µg ( four inhalation ) salbutamol . 5 . Predose FEV1 value first treatment period within range ± 20 % FEV1 measure screen prior salbutamol inhalation . 6 . Patients stable dose regimen 1 . Current smoker , former smoker within last 6 month , exsmokers history 10 packyears . 2 . Patients diagnose COPD . 3 . Recent Respiratory tract infection within 6 week Screening Visit . 4 . Intubation ( ever ) hospitalization longer 24 hour management asthma exacerbation within precede 6 week screen visit . 5 . Clinically significant respiratory condition . 6 . Clinically significant cardiovascular condition . 7 . Patients unable properly use dry powder pMDI inhaler device unable perform acceptable spirometry . 8 . Clinically relevant abnormality laboratory , ECG parameters physical examination result screen evaluation investigator 's opinion , preclude study participation . 9 . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>